NCT02427035View on ClinicalTrials.gov

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions
Acute Myocardial Infarction
Interventions
BIOLOGICAL

CSL112

CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.

OTHER

Placebo

0.9% weight/volume sodium chloride solution (ie, normal saline)

Trial Locations (4)

13353

Study Site - 17101, Berlin

D-81241

Study Site - 17102, Munich

SE1 1YR

Study Site - 24101, London

M13 9WL

Study Site - 24102, Manchester

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY